AGL vs. DXRX, VRCI, GENI, ETX, REDX, VLG, NCYT, CEL, TRX, and AREC
Should you be buying ANGLE stock or one of its competitors? The main competitors of ANGLE include Diaceutics (DXRX), Verici Dx (VRCI), GENinCode (GENI), e-therapeutics (ETX), Redx Pharma (REDX), Venture Life Group (VLG), Novacyt (NCYT), Celadon Pharmaceuticals (CEL), Tissue Regenix Group (TRX), and Arecor Therapeutics (AREC). These companies are all part of the "medical" sector.
ANGLE (LON:AGL) and Diaceutics (LON:DXRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, community ranking, profitability, dividends and earnings.
27.2% of ANGLE shares are owned by institutional investors. Comparatively, 53.2% of Diaceutics shares are owned by institutional investors. 10.7% of ANGLE shares are owned by insiders. Comparatively, 34.5% of Diaceutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
ANGLE received 172 more outperform votes than Diaceutics when rated by MarketBeat users. However, 81.82% of users gave Diaceutics an outperform vote while only 62.20% of users gave ANGLE an outperform vote.
Diaceutics has a net margin of 0.03% compared to ANGLE's net margin of 0.00%. Diaceutics' return on equity of 0.01% beat ANGLE's return on equity.
In the previous week, ANGLE and ANGLE both had 2 articles in the media. ANGLE's average media sentiment score of 0.00 equaled Diaceutics'average media sentiment score.
ANGLE has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500. Comparatively, Diaceutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500.
Diaceutics has higher revenue and earnings than ANGLE.
ANGLE presently has a consensus price target of GBX 70, suggesting a potential upside of 185.71%. Diaceutics has a consensus price target of GBX 150, suggesting a potential upside of 36.55%. Given ANGLE's higher possible upside, research analysts clearly believe ANGLE is more favorable than Diaceutics.
Summary
Diaceutics beats ANGLE on 10 of the 13 factors compared between the two stocks.
Get ANGLE News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
